Pancreatic ductal adenocarcinoma is a relatively uncommon cancer with an almost universally fatal outcome. Chronic pancreatitis (CP) is a risk factor for pancreatic ductal adenocarcinoma (PDA), presumably due to the pro-tumorigenic effects of the inflammatory microenvironment. Besides inflammation, the two diseases have many common features, including ductal metaplasia and fibrosis, both of which may significantly enhance PDA formation. We have found that genetic ablation of the cell surface metalloproteinase ADAM17 specifically from the pancreas makes mice highly resistant to both CP and PDA, thus representing a precise molecular link between these diseases. The purpose of the current proposal is to dissect the mechanisms and define the ADAM17 substrates that contribute to pancreatic disease progression.
In Aim 1 we will use genetic ablation and pharmacological inhibition of ADAM17 substrate-dependent pathways to determine which substrates influence both acinar-to-ductal transdifferentiation and inflammatory cell chemotaxis, in vitro.
In Aim 2, we will use genetic ablation and pharmacological inhibition of the epidermal growth factor receptor (EGFR) and its family member ERRBB3 to test if EGFR ligands released by ADAM17 are responsible for its effects on CP and PDA using in vivo mouse models.
In Aim 3, we will use pharmacological inhibition of ADAM17 released cytokines tumor necrosis factor alpha (TNFa) and interleukin 6 receptor (IL6R) to test for their influence on the etiology of pancreatic inflammation and PDA in vivo.
Pancreatic cancer is virtually always fatal within a very short time after diagnosis. Inflammation of the pancreas has been shown to enhance pancreatic tumor formation. Using genetic mouse models of these diseases, we have found that deletion of the gene encoding the cell surface proteinase ADAM17 protects mice from both pancreatitis and pancreatic cancer formation. The purpose of this proposal is to define the mechanisms by which ADAM17 contributes to these diseases and to assess the potential for designing therapies targeting ADAM17 and the pathways it regulates for treating pancreatic cancer and pancreatitis.
|Hoffmann, Franziska S; Kuhn, Peer-Hendrik; Laurent, Sarah A et al. (2015) The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol 194:542-52|
|Catanzaro, Joseph M; Sheshadri, Namratha; Pan, Ji-An et al. (2014) Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun 5:3729|
|Sheshadri, Namratha; Catanzaro, Joseph M; Bott, Alex J et al. (2014) SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling. Cancer Res 74:6318-29|
|Wu, Chia-Yen C; Carpenter, Eileen S; Takeuchi, Kenneth K et al. (2014) PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 147:1405-16.e7|
|Mehner, Christine; Miller, Erin; Khauv, Davitte et al. (2014) Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Mol Cancer Res 12:1430-9|
|Hall, Jason C; Crawford, Howard C (2014) The conspiracy of autophagy, stress and inflammation in acute pancreatitis. Curr Opin Gastroenterol 30:495-9|
|Bailey, Jennifer M; DelGiorno, Kathleen E; Crawford, Howard C (2014) The secret origins and surprising fates of pancreas tumors. Carcinogenesis 35:1436-40|
|Ray, K C; Moss, M E; Franklin, J L et al. (2014) Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. Oncogene 33:823-31|
|Palazuelos, Javier; Crawford, Howard C; Klingener, Michael et al. (2014) TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination. J Neurosci 34:11884-96|
|DelGiorno, Kathleen E; Tam, Jason W; Hall, Jason C et al. (2014) Persistent salmonellosis causes pancreatitis in a murine model of infection. PLoS One 9:e92807|
Showing the most recent 10 out of 14 publications